ONO Pharmaceutical Co. Ltd., in partnership with Bristol Myers Squibb, has received approval from the European Commission for a new perioperative regimen involving the use of Opdivo® (nivolumab) in combination with chemotherapy, followed by adjuvant Opdivo for the treatment of resectable, high-risk non-small cell lung cancer with PD-L1 expression levels of 1% or more. This approval marks a significant advancement in the treatment options available for patients with this type of lung cancer, supporting ONO Pharmaceutical and Bristol Myers Squibb's ongoing efforts to improve cancer care.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.